Testosterone Gel, 1.62%
Drug
Perrigo Company plc
Total Payments
$118,697
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $118,697 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $118,697 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Bioequivalence study between Perrigo's product and AndroGel 1.62 gel | Perrigo Company plc | $118,697 | 0 |
Top Doctors Receiving Payments for Testosterone Gel, 1.62%
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Newark, DE | $118,697 | 2 |
Ad
Manufacturing Companies
- Perrigo Company plc $118,697
Product Information
- Type Drug
- Total Payments $118,697
- Total Doctors 0
- Transactions 2
About Testosterone Gel, 1.62%
Testosterone Gel, 1.62% is a drug associated with $118,697 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Perrigo Company plc.
Payment data is available from 2017 to 2017. In 2017, $118,697 was paid across 2 transactions to 0 doctors.
The most common payment nature for Testosterone Gel, 1.62% is "Unspecified" ($118,697, 100.0% of total).
Testosterone Gel, 1.62% is associated with 1 research study, including "Bioequivalence study between Perrigo's product and AndroGel 1.62 gel" ($118,697).